Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Melanocyte Stimulating Hormone Receptor Therapeutic Pipeline Market Review, H2 2016

Thursday, October 20, 2016 4:33
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Pipeline Review, H2 2016’, provides in depth analysis on Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted pipeline therapeutics.

The report provides comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693288-melanocyte-stimulating-hormone-receptor-review-h2-2016

 

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
- The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Complete report details @ https://www.wiseguyreports.com/reports/693288-melanocyte-stimulating-hormone-receptor-review-h2-2016

 

 

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Report Coverage 5
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Overview 6
Therapeutics Development 7
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Products under Development by Stage of Development 7
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Products under Development by Therapy Area 8
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Products under Development by Indication 9
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Products under Development by Companies 12
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Companies Involved in Therapeutics Development 21
Clinuvel Pharmaceuticals Limited 21
Mallinckrodt Plc 22
Palatin Technologies, Inc. 23
Retrophin Inc. 24
SolaranRx, Inc. 25
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Drug Profiles 26
afamelanotide – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
AQB-565 – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
corticotropin – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
cosyntropin – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CUV-9900 – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
PL-8176 – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
PL-8177 – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
SRX-1177 – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
VLRX-001 – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Dormant Projects 43
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Discontinued Products 44
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Featured News & Press Releases 45
Aug 03, 2016: Clinuvel prepares New Drug Application for the treatment of erythropoietic protoporphyria 45
Jul 18, 2016: FDA accepts SCENESSE clinical data package for NDA submission 46
Jul 06, 2016: FDA awards SCENESSE Fast Track designation for treatment of EPP 48
Jul 05, 2016: Health Care Resource Use and Costs of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse 49
Jun 22, 2016: Clinuvel’s SCENESSE launched in Europe 50
Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus 50
May 26, 2016: Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property 52
May 18, 2016: German Porphyria Expert Centres to start distribution of SCENESSE (afamelanotide 16mg) 53
May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome 53
Mar 24, 2016: NICE’s technical team invited stakeholders with an interest in the treatment of erythropoietic protoporphyria 54
Feb 16, 2016: Clinuvel brief on European commercialisation 55
Feb 12, 2016: SCENESSE receives US FDA orphan designation for cutaneous porphyrias 55
Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study 56
Dec 03, 2015: Update on North American vitiligo program for SCENESSE 58
Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

Get It Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693288

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.